278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
The Readout Loud
00:00
Rejection of Treatment by Al Nylon and Its Impact
This chapter explores the recent rejection of a treatment by Al Nylon, a biotech company, by the FDA and its implications for the company's future and their upcoming subcutaneous treatment. It emphasizes the uncertainty biotech companies face in terms of treatment efficacy.
Transcript
Play full episode
